Loading...
NASDAQ: DXCM
DexCom, Inc.
Healthcare · Medical - Devices
●S&P 500 since 2020
Market Cap
$26.46B
52w High
$89.98
52w Low
$54.11
P/E
31.37
Volume
275.50K
Outstanding Shares
390.02M
Company profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
CEOJacob Steven Leach
SectorHealthcare
IndustryMedical - Devices
Employees10,200
IPO dateApr 14, 2005
Valuation
Forward P/E—
EV/EBITDA22.66
Enterprise value$26.37B
Stock splits
Jun 13, 20224:1
Profitability & growth
Revenue growth13.12%
Gross margin60.1%▼0.59%vs FY2024
Operating margin19.56%▲31.46%vs FY2024
ROE30.46%▲11.13%vs FY2024
Analyst consensus
RatingBuy
Target price$85.82▲26.48%
42
Buy
8
Hold
2
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$0.48
$0.44
Q3FY25
ActualEst.
$0.61
$0.58
Q4FY25
ActualEst.
$0.68
$0.65
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.16B
$1.12B
Q3FY25
ActualEst.
$1.21B
$1.18B
Q4FY25
ActualEst.
$1.26B
$1.25B
Q1FY26
Next Est.
—